title: [Dopaminergic stimulation in the non-motor symptoms of Parkinson's disease].
abstract: BACKGROUND
  The non-motor symptoms of Parkinson's disease have a great impact in terms of quality of life. They are frequently underdiagnosed and clinical experience suggests that not only is dopamine therapy ineffective but that in many cases it is also responsible for the appearance of some of these symptoms. Different studies have drawn attention to the involvement of the dopaminergic pathways in the pathogenesis of some non-motor symptoms. It has been observed that they can undergo fluctuations in relation to dopaminergic stimulation, generally in wearing off states, while displaying a significant correlation with motor fluctuations and a clinical response with continuous dopaminergic therapy.
  
  
  CONCLUSIONS
  Although recent reviews offer insufficient evidence for treatment of non-motor symptoms with dopaminergic therapy, involvement of the dopaminergic pathways in the aetiopathogenesis of some of these disorders and the clinical observation that such symptoms undergo fluctuations in relation to pulsatile dopaminergic stimulation may lead us to reconsider the possible role of dopaminergic therapy in the treatment of these symptoms.
authors.affiliation: Hospital General de Segovia, España.
authors.forename: A
authors.initials: A
authors.lastname: Martínez-Pueyo
authors.forename: N
authors.initials: N
authors.lastname: Berrocal-Izquierdo
authors.forename: A
authors.initials: A
authors.lastname: Castrillo-Sanz
authors.forename: J S
authors.initials: JS
authors.lastname: Rodríguez-Vico
mesh_terms: D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004066:Digestive System Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006970:Disorders of Excessive Somnolence / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D018491:Dopamine Agonists / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D020923:REM Sleep Parasomnias / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D012891:Sleep Apnea Syndromes / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D014570:Urologic Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology
chemical_list: D018491:Dopamine Agonists; D007980:Levodopa